Tollys presents scientific data supporting preclinical proof of concept for TL-532, its cancer immunotherapy drug candidate
Doctors Marc Bonnin and Sylvain Thierry will present Tollys’ results at the EACR 2021 Congress, which will take place from June 9 -12. We’re proud to be able to share this data, which proves the potential of this specific TLR3 agonist in immuno-oncology, in particular by releasing tumor-specific antigens.
Confirmation by MATWIN’s panel of scientific and industry experts of therapeutic potential of TL-532 major boost for Tollys, supports moving flagship product towards clinical phase.
Drawing on her expertise, Dr. Zinaï will be supporting Tollys in its early clinical developments.
Professor Jean-Yves Blay, current member of the scientific advisory board, takes up chairmanship as company prepares to launch clinical programs.
With more than 35 years experience in the pharmaceutical industry and biotech, Philippe Goupit will lead Tollys’ plans for growth.
Cutting-Edge Cancer Immunotherapy
60F avenue Rockefeller
69008 Lyon, FRANCE